The potential utility of N-succinimidyl 5-iodo-3-pyridinecarboxylate (SIPC) for the radioiodination of monoclonal antibodies was investigated. Paired-label studies were performed using the anti-tenascin antibody 81C6 in athymic mice bearing subcutaneous D-54 MG human glioma xenografts. Radiolabeling was also done using N-succinimidyl 3-iodobenzoate (SIB). Radioiodination of SIPC and SIB both proceeded in 60-80% yield, but protein coupling efficiencies with SIB were higher (76 +/- 16 vs 60 +/- 7%). Immunoreactivity and affinity of both preparations were similar. Using SIPC, thyroid uptake was quite low, decreasing from 0.3% at day 1 to 0.05% at day 8. Tumor uptake reached 46 +/- 11% injected dose/g at day 1 but declined gradually thereafter. This apparent decline reflected the rapid growth of these xenografts since tumor accumulation expressed as percentage of injected dose remained nearly constant up to day 9. These results suggest that SIPC, like SIB, offers significant advantages for labeling antibodies when compared with conventional protein iodination methods.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/0969-8051(93)90149-o | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Preliminary Research of Radiolabeled Atezolizumab for the Noninvasive Evaluation of TNBC PD-L1 Expression In Vivo.
J Labelled Comp Radiopharm
September 2024
Shanghai Institute of Applied Physics, Chinese Academy of Sciences, Shanghai, China.
Article Synopsis
- PD-L1 expression is linked to how well triple-negative breast cancer treatments work and patient outcomes.
- The study synthesized a new imaging agent, [I]PI-Atezolizumab, which showed stability in lab settings and maintained effective binding to PD-L1 without losing its affinity.
- Animal studies demonstrated that [I]PI-Atezolizumab has better stability and targeted imaging capabilities for PD-L1, proving useful for monitoring in triple-negative breast cancer models.
Radioiodination, purification, and evaluation of antihuman tumor-derived immunoglobulin G light chain monoclonal antibody in tumor-bearing nude mice.
J Labelled Comp Radiopharm
March 2023
Department of Nuclear Medicine, Peking University First Hospital, Beijing, China.
We report the synthesis and biological evaluation of I-labeled antihuman tumor-derived immunoglobulin G (IgG) light chain monoclonal antibody (4E9) ([ I]I-4E9) as a promising probe for tumor imaging. [ I]I-4E9 was synthesized in radiochemical yield of 89.9 ± 4.
View Article and Find Full Text PDFPhase 1 study of intraventricular I-omburtamab targeting B7H3 (CD276)-expressing CNS malignancies.
J Hematol Oncol
November 2022
Departments of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 429, New York, NY, 10065, USA.
Background: The prognosis for metastatic and recurrent tumors of the central nervous system (CNS) remains dismal, and the need for newer therapeutic targets and modalities is critical. The cell surface glycoprotein B7H3 is expressed on a range of solid tumors with a restricted expression on normal tissues. We hypothesized that compartmental radioimmunotherapy (cRIT) with the anti-B7H3 murine monoclonal antibody omburtamab injected intraventricularly could safely target CNS malignancies.
View Article and Find Full Text PDFAdvancing Zr-immuno-PET in neuroscience with a bispecific anti-amyloid-beta monoclonal antibody - The choice of chelator is essential.
Theranostics
October 2022
Amsterdam UMC location Vrije Universiteit Amsterdam, dept Radiology & Nuclear Medicine, De Boelelaan 1117, Amsterdam, The Netherlands.
The accelerated approval of the monoclonal antibody (mAb) aducanumab as a treatment option for Alzheimer's Disease and the continued discussions about its efficacy have shown that a better understanding of immunotherapy for the treatment of neurodegenerative diseases is needed. Zr-immuno-PET could be a suitable tool to open new avenues for the diagnosis of CNS disorders, monitoring disease progression, and assessment of novel therapeutics. Herein, three different Zr-labeling strategies and direct radioiodination with I of a bispecific anti-amyloid-beta aducanumab derivate, consisting of aducanumab with a C-terminal fused anti-transferrin receptor binding single chain Fab fragment derived from 8D3 (Adu-8D3), were compared and with regard to brain uptake and target engagement in an APP/PS1 Alzheimer's disease mouse model and wild type animals.
View Article and Find Full Text PDFRadiolabeling and cytotoxicity of monoclonal antibody Isatuximab functionalized silver nanoparticles on the growth of multiple myeloma.
Int J Pharm
August 2022
Labeled Compounds Department, Hot Labs. Center, Egyptian Atomic Energy Authority (EAEA), P.O. Box 13759, Cairo, Egypt.
The goal of this article was to develop a new therapeutic strategy based on nanotechnology for multiple myeloma (MM) treatment which shows a synergism of different mechanisms. In this concern, 12.9 nm-sized silver nanoparticles (AgNPs) were prepared and functionalized with Isatuximab, anti-MM monoclonal antibody (mAb).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!